Modifying chemotherapeutic management of a patient with Burkitt's lymphoma and pre-existing motor neurone disease

J Clin Pharm Ther. 2015 Aug;40(4):483-5. doi: 10.1111/jcpt.12293. Epub 2015 Jun 13.

Abstract

What is known and objective: Intensive chemotherapy for treatment of Burkitt's lymphoma (BL) - a high-grade lymphoproliferative disorder (LPD) - can cause neurotoxicity. An association between motor neurone disease (MND) and LPDs has previously been described, but there is a lack of recommendations available to guide management of such patients. This report aims to describe suitable management of BL in a patient with MND.

Case description: A 66-year-old woman with a history of MND affecting her limbs was diagnosed with bulky, extranodal, high-risk gastric BL. Standard chemotherapy is with multiple non-cross-resistant cytotoxic agents. To avoid exacerbation of neuropathy, six cycles of a modified regimen was planned, aiming to minimize exposure to the most neurotoxic agents. A PET-FDG-negative remission was obtained at 12 months, without the signs of central neurotoxicity, peripheral neuropathy or muscle weakness.

What is new and conclusion: High-intensity chemotherapy, minimizing known neurotoxic agents, was delivered safely and effectively in a patient with BL and pre-existing MND. More case descriptions are required to guide management decisions.

Keywords: Burkitt's lymphoma; chemotherapy; lymphoma; motor neurone disease; neuropathy; neurotoxicity.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Burkitt Lymphoma / drug therapy*
  • Burkitt Lymphoma / pathology
  • Female
  • Fluorodeoxyglucose F18 / administration & dosage
  • Humans
  • Motor Neuron Disease / complications*
  • Neurotoxicity Syndromes / prevention & control*
  • Positron-Emission Tomography / methods
  • Radiopharmaceuticals / administration & dosage
  • Remission Induction / methods

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18